Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Orchard Therapeutics Plc's Business Segments
Orchard Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 6
Regions Reported
-
Orchard Therapeutics Plc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Libmeldy88.2%
- Product Revenue, Net88.2%
- Collaboration Revenue11.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Libmeldy | $ 6 | 88.2% |
| Product Revenue, Net | $ 6 | 88.2% |
| Collaboration Revenue | $ 1 | 11.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Orchard Therapeutics Plc
Orchard Therapeutics Plc is a biotechnology company focused on developing and commercializing gene therapies for severe and life-threatening rare diseases. The company was founded in 2016 and is headquartered in London, United Kingdom.
The main objective of Orchard Therapeutics is to address the limitations of traditional treatment options for rare diseases by employing cutting-edge gene therapy techniques. The company harnesses the potential of gene therapy to correct specific genetic mutations that cause these rare diseases, aiming to provide long-term solutions and improve patients' quality of life.
Orchard Therapeutics has a robust and diversified pipeline that covers various rare diseases, including primary immunodeficiencies, metabolic disorders, and hematological disorders. The company's most advanced product candidate, OTL-101, is being developed for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare genetic disorder characterized by a compromised immune system.
OTL-101 is designed to introduce a functional copy of the adenosine deaminase (ADA) gene into the patient's own stem cells, which can then differentiate and produce healthy immune cells. Early-stage clinical trials have shown promising results, with a high proportion of patients achieving immune reconstitution and improved overall survival rates.
Aside from OTL-101, Orchard Therapeutics has developed multiple other investigational gene therapies. Some notable candidates include OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, and OTL-102 for X-linked chronic granulomatous disease. These therapies utilize similar gene delivery approaches to correct the specific genetic mutations causing the respective diseases.
The company has established strategic collaborations and partnerships with various organizations to accelerate the development and commercialization of its gene therapies. This includes agreements with academic institutions, research organizations, and pharmaceutical companies. Orchard Therapeutics also actively engages with patient advocacy groups to ensure the patient's perspective is integrated into its development efforts.
In addition to its extensive pipeline, Orchard Therapeutics has invested in a state-of-the-art manufacturing facility located in California, USA. The facility is equipped with the necessary infrastructure to produce lentiviral vectors, the key component of gene therapy, at a large scale. This vertical integration enables Orchard Therapeutics to have greater control over its manufacturing process and facilitate efficient production of its gene therapies.
Overall, Orchard Therapeutics Plc is a pioneering biotechnology company with a clear focus on developing transformative gene therapies for rare diseases. With a strong pipeline, strategic collaborations, and a commitment to patient-centric innovation, the company strives to bring hope and better treatment options to patients and families affected by these debilitating conditions.
The main objective of Orchard Therapeutics is to address the limitations of traditional treatment options for rare diseases by employing cutting-edge gene therapy techniques. The company harnesses the potential of gene therapy to correct specific genetic mutations that cause these rare diseases, aiming to provide long-term solutions and improve patients' quality of life.
Orchard Therapeutics has a robust and diversified pipeline that covers various rare diseases, including primary immunodeficiencies, metabolic disorders, and hematological disorders. The company's most advanced product candidate, OTL-101, is being developed for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare genetic disorder characterized by a compromised immune system.
OTL-101 is designed to introduce a functional copy of the adenosine deaminase (ADA) gene into the patient's own stem cells, which can then differentiate and produce healthy immune cells. Early-stage clinical trials have shown promising results, with a high proportion of patients achieving immune reconstitution and improved overall survival rates.
Aside from OTL-101, Orchard Therapeutics has developed multiple other investigational gene therapies. Some notable candidates include OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, and OTL-102 for X-linked chronic granulomatous disease. These therapies utilize similar gene delivery approaches to correct the specific genetic mutations causing the respective diseases.
The company has established strategic collaborations and partnerships with various organizations to accelerate the development and commercialization of its gene therapies. This includes agreements with academic institutions, research organizations, and pharmaceutical companies. Orchard Therapeutics also actively engages with patient advocacy groups to ensure the patient's perspective is integrated into its development efforts.
In addition to its extensive pipeline, Orchard Therapeutics has invested in a state-of-the-art manufacturing facility located in California, USA. The facility is equipped with the necessary infrastructure to produce lentiviral vectors, the key component of gene therapy, at a large scale. This vertical integration enables Orchard Therapeutics to have greater control over its manufacturing process and facilitate efficient production of its gene therapies.
Overall, Orchard Therapeutics Plc is a pioneering biotechnology company with a clear focus on developing transformative gene therapies for rare diseases. With a strong pipeline, strategic collaborations, and a commitment to patient-centric innovation, the company strives to bring hope and better treatment options to patients and families affected by these debilitating conditions.
Orchard Therapeutics Plc is a biotechnology company that is at the forefront of developing and commercializing gene therapies specifically designed to treat rare genetic diseases. Their innovative approach focuses on gene editing and replacement therapies, addressing the root causes of these conditions and aiming to deliver long-lasting, potentially curative benefits to patients.
Segments
Orchard Therapeutics operates in several key segments within the biotechnology industry, predominantly related to gene therapy:
1. Research and Development (R&D):
The foundation of Orchard Therapeutics success lies in its robust R&D efforts. The company dedicates significant resources to identifying, designing, and validating new gene therapy candidates. This segment involves a range of activities, including:
- Scientific Research: Exploration of genetic pathways and mutations that give rise to rare diseases, alongside the discovery of potential therapeutic genes.
- Preclinical Testing: Conducting laboratory and animal studies to assess the safety and effectiveness of new therapies before they proceed to clinical trials.
- Clinical Trials: Orchestrating phased trials with human subjects to rigorously test the therapies in terms of safety, efficacy, dosage, and delivery methods. These trials are critical for generating the necessary data required for regulatory approvals.
2. Manufacturing and Supply Chain:
Orchard Therapeutics has built advanced manufacturing capabilities to produce their gene therapies at scale. This segment is pivotal for ensuring that the therapies can be consistently produced and delivered to healthcare providers efficiently. Key components include:
- State-of-the-Art Facilities: These facilities are equipped with cutting-edge technology and processes to manufacture cell and gene therapies under stringent regulatory standards.
- Quality Control and Assurance: Rigorous testing and quality assurance processes are implemented throughout the manufacturing cycle to ensure product safety and effectiveness.
- Supply Chain Management: A well-established supply chain ensures timely distribution of therapies to hospitals and clinics, facilitating patient access across different regions.
3. Commercialization and Marketing:
Post-approval, Orchard Therapeutics is involved in the commercialization of its therapeutics. This segment encompasses:
- Market Research and Strategy: Understanding market dynamics, patient needs, and potential barriers to access, allowing the company to devise strategic marketing plans.
- Healthcare Provider Engagement: Working closely with healthcare professionals to educate them about the new therapies, their clinical benefits, and administration protocols.
- Patient Access Programs: Implementing programs to enhance accessibility, including patient registries, financial assistance, and support networks.
Products and Services
Orchard Therapeutics provides a variety of cutting-edge gene therapies specifically targeting rare genetic disorders. Some of the most notable products and services include:
1. OTL-101:
- Indication: Designed for treating adenosine deaminase severe combined immunodeficiency (ADA-SCID), a severe immune deficiency that can lead to life-threatening infections.
- Mechanism of Action: OTL-101 aims to correct the underlying genetic defect by delivering a functional copy of the ADA gene into the patients stem cells, which can then reproduce the normal enzyme, thereby restoring immune functionality.
2. OTL-200:
- Indication: This therapy is aimed at metachromatic leukodystrophy (MLD), a devastating neurological condition that leads to severe disability and early death.
- Mechanism of Action: OTL-200 operates by introducing a functional copy of the arylsulfatase A gene into patients stem cells, thereby fixing the genetic defect and allowing for proper nerve myelination.
3. OTL-103:
- Indication: Targeting Wiskott-Aldrich syndrome (WAS), a rare immune system disorder characterized by eczema, allergies, and an increased risk of infections.
- Mechanism of Action: OTL-103 works by inserting a healthy copy of the WAS gene into hematopoietic stem cells, restoring normal immune function and reducing disease symptoms.
4. Post-Treatment Care:
- Orchard Therapeutics emphasizes comprehensive post-treatment care, which includes monitoring patient outcomes, managing potential side effects, and providing personalized medical supervision to ensure the best possible recovery and quality of life post-therapy.
5. Collaborations:
- The company actively engages in partnerships with academic institutions, research organizations, and other biotech firms. These collaborations aim to further gene therapy research, amplify their therapy pipeline, and refine treatment modalities to enhance patient outcomes.
Conclusion
In summary, Orchard Therapeutics is dedicated to developing and commercializing groundbreaking gene therapies for rare diseases. Their comprehensive approach encompasses rigorous research and development, advanced manufacturing processes, effective commercialization strategies, supportive post-treatment care, and collaborative efforts to expand the frontiers of gene therapy. By addressing both the medical and logistical challenges of treating rare diseases, Orchard Therapeutics strives to significantly improve the lives of patients facing these challenging conditions.
Segments
Orchard Therapeutics operates in several key segments within the biotechnology industry, predominantly related to gene therapy:
1. Research and Development (R&D):
The foundation of Orchard Therapeutics success lies in its robust R&D efforts. The company dedicates significant resources to identifying, designing, and validating new gene therapy candidates. This segment involves a range of activities, including:
- Scientific Research: Exploration of genetic pathways and mutations that give rise to rare diseases, alongside the discovery of potential therapeutic genes.
- Preclinical Testing: Conducting laboratory and animal studies to assess the safety and effectiveness of new therapies before they proceed to clinical trials.
- Clinical Trials: Orchestrating phased trials with human subjects to rigorously test the therapies in terms of safety, efficacy, dosage, and delivery methods. These trials are critical for generating the necessary data required for regulatory approvals.
2. Manufacturing and Supply Chain:
Orchard Therapeutics has built advanced manufacturing capabilities to produce their gene therapies at scale. This segment is pivotal for ensuring that the therapies can be consistently produced and delivered to healthcare providers efficiently. Key components include:
- State-of-the-Art Facilities: These facilities are equipped with cutting-edge technology and processes to manufacture cell and gene therapies under stringent regulatory standards.
- Quality Control and Assurance: Rigorous testing and quality assurance processes are implemented throughout the manufacturing cycle to ensure product safety and effectiveness.
- Supply Chain Management: A well-established supply chain ensures timely distribution of therapies to hospitals and clinics, facilitating patient access across different regions.
3. Commercialization and Marketing:
Post-approval, Orchard Therapeutics is involved in the commercialization of its therapeutics. This segment encompasses:
- Market Research and Strategy: Understanding market dynamics, patient needs, and potential barriers to access, allowing the company to devise strategic marketing plans.
- Healthcare Provider Engagement: Working closely with healthcare professionals to educate them about the new therapies, their clinical benefits, and administration protocols.
- Patient Access Programs: Implementing programs to enhance accessibility, including patient registries, financial assistance, and support networks.
Products and Services
Orchard Therapeutics provides a variety of cutting-edge gene therapies specifically targeting rare genetic disorders. Some of the most notable products and services include:
1. OTL-101:
- Indication: Designed for treating adenosine deaminase severe combined immunodeficiency (ADA-SCID), a severe immune deficiency that can lead to life-threatening infections.
- Mechanism of Action: OTL-101 aims to correct the underlying genetic defect by delivering a functional copy of the ADA gene into the patients stem cells, which can then reproduce the normal enzyme, thereby restoring immune functionality.
2. OTL-200:
- Indication: This therapy is aimed at metachromatic leukodystrophy (MLD), a devastating neurological condition that leads to severe disability and early death.
- Mechanism of Action: OTL-200 operates by introducing a functional copy of the arylsulfatase A gene into patients stem cells, thereby fixing the genetic defect and allowing for proper nerve myelination.
3. OTL-103:
- Indication: Targeting Wiskott-Aldrich syndrome (WAS), a rare immune system disorder characterized by eczema, allergies, and an increased risk of infections.
- Mechanism of Action: OTL-103 works by inserting a healthy copy of the WAS gene into hematopoietic stem cells, restoring normal immune function and reducing disease symptoms.
4. Post-Treatment Care:
- Orchard Therapeutics emphasizes comprehensive post-treatment care, which includes monitoring patient outcomes, managing potential side effects, and providing personalized medical supervision to ensure the best possible recovery and quality of life post-therapy.
5. Collaborations:
- The company actively engages in partnerships with academic institutions, research organizations, and other biotech firms. These collaborations aim to further gene therapy research, amplify their therapy pipeline, and refine treatment modalities to enhance patient outcomes.
Conclusion
In summary, Orchard Therapeutics is dedicated to developing and commercializing groundbreaking gene therapies for rare diseases. Their comprehensive approach encompasses rigorous research and development, advanced manufacturing processes, effective commercialization strategies, supportive post-treatment care, and collaborative efforts to expand the frontiers of gene therapy. By addressing both the medical and logistical challenges of treating rare diseases, Orchard Therapeutics strives to significantly improve the lives of patients facing these challenging conditions.